Ana Pena, PhD,  —

Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.

Articles by Ana Pena

Vertex Partners with Ribometrix to Discover RNA-targeted Therapies

Vertex Pharmaceuticals has entered a strategic collaboration with Ribometrix to discover potential RNA-targeted therapies for serious diseases. Vertex is a leader in the market of CFTR modulators for cystic fibrosis (CF), and is the developer of Kalydeco (ivacaftor), Orkambi (ivacaftor/lumacaftor), and Symdeko (tezacaftor/ivacaftor combination therapy), three approved CF…

Pancreas-on-a-chip Expected to Shed Light, Help Find New Treatments for CF-related Diabetes

Scientists have created a miniature human pancreas-on-a-chip that may help identify the cause of cystic fibrosis-related diabetes (CFRD), a common and life-threatening complication of cystic fibrosis (CF). Researchers believe the pancreas-on-a-chip will provide insightful information about the biology of CFRD, offering a reliable way to monitor pancreatic cell responses and…

Phage Therapy May Help Resolve Multidrug-resistant Pseudomonas Airway Infections, Case Report Suggests

Armata Pharmaceuticals‘ investigational phage therapy AP-PA01 combined with antibiotics holds promise for treating multidrug-resistant Pseudomonas airway infections, updated data from a case study show. A young woman with cystic fibrosis (CF) was successfully treated for a multidrug-resistant Pseudomonas aeruginosa pneumonia using AP-PA01 and antibiotics. At 100 days…